.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average consequence of 11 months, individuals along with metastatic stomach tumors that received biomarker-matched treatments based on flowing tumor DNA profiling showed a greater scientific benefit than those receiving unmatched treatment.